Last 12 months
Inside the activity.
4 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 1 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 1 | 0 |
| Oct 2026 | 0 | 4 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2017 Filed Feb 22, 2017 23:45 UTC |
Cola MarkDirector · President, CEO and COO
|
GrantStock Option (right to buy) · Derivative | 123,750 | $0.00 Strike: $3.48 | $0.00 |
DisclosureSEC source: 0001250853-17-000033 · primary_doc.xml · derivative · entry 1 Cola Mark · CIK 0001698162 · Director · President, CEO and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,750 Underlying: Common Stock · 123,750 shares Expires 2027-02-20 F1 · derivative.exercise_date: The stock option will vest in six equal quarterly installments over an 18-month period from the date of grant. Read SEC document |
| February 15, 2017 Filed Feb 16, 2017 02:57 UTC |
Rice John ReynoldsDirector
|
GrantCommon Stock | 5,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001250853-17-000032 · primary_doc.xml · nonDerivative · entry 1 Rice John Reynolds · CIK 0001698204 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,231 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.